Logo

Thermo Fisher Scientific Completes Sale of Genevac

Apr 04, 2007
NEW YORK (GenomeWeb News) — Thermo Fisher Scientific today said it has completed the sale of its Genevac business to Riverlake Equity Partners.
 
Thermo said Genevac brought in around $17 million in annual sales.
 
As GenomeWeb News reported last October, the Federal Trade Commission and the European Commission required that Fisher Scientific divest the Ipswich, UK-based company before it can merge with Thermo Electron.
 
The FTC and the EC required Thermo to sell the business by April 9.

Breaking News
The Scan

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.

Sequencing Study Leads to Vaccine Target in Bacteria Behind Neonatal Meningitis

Researchers eBioMedicine track down potential vaccine targets with transposon sequencing on mutant bacteria causing neonatal meningitis in mouse models of the disease.

Multiple Myeloma Progression Influenced by Immune Microenvironment Expression

Researchers in NPJ Genomic Medicine compare RNA sequencing profiles of 102,207 individual cells in bone marrow samples from 18 individuals with rapid or non-progressing multiple myeloma.

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.